Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $143.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 66.27% year-over-year to $143.5 million; the TTM figure through Mar 2026 stood at $143.5 million (up 66.27% YoY), while the FY2025 annual figure was $135.7 million, up 68.33% from the prior year.
• Total Current Liabilities was $143.5 million for Q1 2026 at Tarsus Pharmaceuticals, up from $135.7 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $143.5 million in Q1 2026 to a low of $11.7 million in Q2 2022.
• Historically, Total Current Liabilities has averaged $56.2 million across 5 years, with a median of $42.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities rose 5.11% in 2023, then soared 249.28% in 2024.
• A 5-year view of Total Current Liabilities shows it stood at $15.4 million in 2022, then surged by 139.39% to $36.9 million in 2023, then soared by 118.25% to $80.6 million in 2024, then jumped by 68.33% to $135.7 million in 2025, then rose by 5.76% to $143.5 million in 2026.
• The last three Total Current Liabilities figures came in at $143.5 million (Q1 2026), $135.7 million (Q4 2025), and $117.0 million (Q3 2025), per Business Quant data.